Kantor A - Search Results

1

Horizon Scan Of Clinical Laboratories Offering Pharmacogenetic Testing.

Haga SB, Kantor A. Haga SB, et al. Among authors: kantor a. Health Aff (Millwood). 2018 May;37(5):717-723. doi: 10.1377/hlthaff.2017.1564. Health Aff (Millwood). 2018. PMID: 29733708 Free PMC article.

2

The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine.

Kantor A, Haga SB. Kantor A, et al. J Pers Med. 2021 Jan 14;11(1):45. doi: 10.3390/jpm11010045. J Pers Med. 2021. PMID: 33466644 Free PMC article.

3

CRISPR genome engineering for retinal diseases.

Kantor A, McClements ME, Peddle CF, Fry LE, Salman A, Cehajic-Kapetanovic J, Xue K, MacLaren RE. Kantor A, et al. Prog Mol Biol Transl Sci. 2021;182:29-79. doi: 10.1016/bs.pmbts.2021.01.024. Epub 2021 Mar 19. Prog Mol Biol Transl Sci. 2021. PMID: 34175046

4

Genome-Editing Strategies for Treating Human Retinal Degenerations.

Quinn J, Musa A, Kantor A, McClements ME, Cehajic-Kapetanovic J, MacLaren RE, Xue K. Quinn J, et al. Among authors: kantor a. Hum Gene Ther. 2021 Mar;32(5-6):247-259. doi: 10.1089/hum.2020.231. Epub 2020 Nov 19. Hum Gene Ther. 2021. PMID: 32993386 Free PMC article. Review.

5

CRISPR-Cas9 DNA Base-Editing and Prime-Editing.

Kantor A, McClements ME, MacLaren RE. Kantor A, et al. Int J Mol Sci. 2020 Aug 28;21(17):6240. doi: 10.3390/ijms21176240. Int J Mol Sci. 2020. PMID: 32872311 Free PMC article. Review.

6

Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?

Han RC, Fry LE, Kantor A, McClements ME, Xue K, MacLaren RE. Han RC, et al. Among authors: kantor a. Expert Opin Orphan Drugs. 2021;9(1):13-24. doi: 10.1080/21678707.2021.1882300. Epub 2021 Mar 24. Expert Opin Orphan Drugs. 2021. PMID: 34040899 Free PMC article.

7

Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations.

Salman A, Kantor A, McClements ME, Marfany G, Trigueros S, MacLaren RE. Salman A, et al. Among authors: kantor a. Pharmaceutics. 2022 Sep 1;14(9):1842. doi: 10.3390/pharmaceutics14091842. Pharmaceutics. 2022. PMID: 36145593 Free PMC article. Review.

8

Changes in trends of visits and service utilization by mental health patients in the community: a twelve-year study in Israel.

Shalom MM, Kantor A, Azuri E, Pirian DT, Kertes J, Hemo B, Shmueli T. Shalom MM, et al. Among authors: kantor a. Isr J Health Policy Res. 2025 Dec 19;14(1):78. doi: 10.1186/s13584-025-00735-y. Isr J Health Policy Res. 2025. PMID: 41413905 Free PMC article.

9

Development of a humanized anti-fibrin monoclonal antibody for the treatment of neuroinflammatory and retinal diseases.

Kantor AB, Rickert M, Cheng H, Flanagan K, Salgotra V, Suppahia A, Ryu JK, Widboom PF, Warfield JR, Akassoglou K, Stavenhagen JB. Kantor AB, et al. J Neuroinflammation. 2025 Dec 17. doi: 10.1186/s12974-025-03650-w. Online ahead of print. J Neuroinflammation. 2025. PMID: 41408289 Free article. No abstract available.

10

The Bounce-Back Effect: What Happens After Cessation of Low-Dose Semaglutide in People with HIV.

Erlandson KM, Kitch DW, Kantor A, Belaunzaran-Zamudio PF, Brown TT, Fichtenbaum CJ, Heath SL, Sattler F, Lake JE. Erlandson KM, et al. Among authors: kantor a. Clin Infect Dis. 2025 Nov 26:ciaf652. doi: 10.1093/cid/ciaf652. Online ahead of print. Clin Infect Dis. 2025. PMID: 41299212

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

237 results

Search Page

Filters